ESPR Q3 2019 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q3 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$981,000

Gross Profit

-$47M-4821.6% margin

Operating Income

-$66M-6704.2% margin

Net Income

-$68M-6970.1% margin

EPS (Diluted)

$-2.52

QoQ Revenue Growth

-0.1%

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$58M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$255M

Total Liabilities

$187M

Stockholders' Equity

$69M

Cash & Equivalents

$212M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$981,000	$0	—
Gross Profit	-$47M	-$42M	-13.8%
Operating Income	-$66M	-$51M	-30.1%
Net Income	-$68M	-$50M	-37.0%

Revenue Segments

Ongoing Regulatory And Development Activities Revenue

$1M100%